TRVI

13.4402.04%
TR

Thomas R. Sciascia

Co-Founder & Chief Scientific Officer

Dr. Thomas R. Sciascia, M.D., co-founded Trevi Therapeutics, Inc 2011 and serves as Chief Scientific Officer since November 2022 and had been its Chief Medical Officer since March 2011 until November 2022 and served as Chief Science Officer from November 2022. Dr. Sciascia served as Executive Vice President, Research and Development at Trevi Therapeutics, Inc. He was oversees R&D strategy, compound selection and the execution of all drug development work. Dr. Sciascia has an extensive background in clinical development and regulatory strategy. Dr. Sciasci served as Chief Medical Officer of Penwest Pharmaceuticals Company since 2001. He served as Senior Vice President at Penwest Pharmaceuticals Co. since 2001 till 2010. Dr. Sciascia's drug development experience at Penwest included the development of orphan drugs, of which the most recent reported statistically significant results in a Phase II trial. Prior to working at Penwest, Dr. Sciascia worked at Quintiles, Inc. as a consultant to pharma and biotechnology companies. He also worked as a Medical Director at Transkaryotic Therapeutics from 2000 till 2001. Dr. Sciasci served as Vice President of Clinical Operations for Penwest Pharmaceuticals Co. since 2001. He served as Senior Vice President of Clinical Development and Regulatory Affairs at Penwest Pharmaceuticals Company since 2009. He served as Medical Director of Quintiles Inc. from 1997 to 2000. He served as Chairman and Member of Clinical Advisory Board at Trevi Therapeutics, Inc. since March 2013. He is a board certified neurologist licensed to practice medicine in the state of Massachusetts. Dr. Sciascia received a Bachelors of Science Degree in Biology at Massachusetts Institute of Technology and a Medical Degree at Columbia University.

Positions